Introduction {#Sec1}
============

The breast cancer rate tends to peak at a younger range in Japan than in Western countries \[[@CR1]--[@CR3]\]. About half of breast cancer diagnoses in Japan are for patients in their 30s--50s \[[@CR2]\]. As this pattern probably reflects their genetic background, investigations of hereditary breast and ovarian cancer (HBOC) are important for Japanese women. The Japanese nationwide HBOC registration system aims to clarify clinical and genetic features of Japanese HBOC and to improve its medical treatment.

The Japanese HBOC Consortium (JHC) was established in December 2012. We established a registration committee for JHC in October 2013 and promoted it as a nationwide registration project. The registered subjects were all Japanese individuals who underwent *BRCA1*/*2* genetic testing (including individuals in which no mutation was detected) \[[@CR4]\]. Here, we report results of the HBOC Registration from its establishment until 2016. The objective of the current study is to analyze the information of the Japanese pedigrees, who underwent *BRCA1*/*2* genetic testing, and to make use of the results in clinical practice.

Prophylactic surgery, such as prophylactic mastectomy (PM), is a preemptive strategy for HBOC. As PM can reduce risk of breast cancer by \> 90%, it is often performed among *BRCA1*/*2* mutation (*BRCA1*/*2*^*MUT*^) carriers. Reportedly, occult cancers are detected in 0.5--9.9% of PM specimens \[[@CR5]--[@CR15]\].

Methods {#Sec2}
=======

This study included subjects who underwent *BRCA1*/*2* genetic testing until 2016. As of 2016, 7 participating medical institutions were enrolled: St. Luke's International Hospital (Tokyo), Cancer Institute Hospital (Tokyo), Showa University Hospital (Tokyo), Hoshi General Hospital (Fukushima), Kitano Hospital (Osaka), Shikoku Cancer Center (Ehime), and Kochi Medical School Hospital (Kochi).

All subjects, who received genetic counseling and underwent genetic testing of their own free will in clinical practice, were those who had been provided explanations of the HBOC risk in accordance with Genetic/Familial High-Risk Assessment: Breast and Ovarian in NCCN Guidelines \[[@CR16]\]. Most of genetic testing with sequencing and large rearrangement analysis was performed at Myriad Genetic Laboratories or FALCO Biosystems. Detected variants were interpreted by the criteria of Myriad Genetic Laboratories. We entered information for *BRCA1*/*2* genetic testing and clinicopathological findings of breast cancer, ovarian cancer, and other cancers in the original electronic template. All data except sex were anonymously registered in each institution. Dates of birth only included year and month \[[@CR4]\].

In the cases of PM, we examined breasts with the use of mammography (MMG), ultrasound (US), and magnetic resonance imaging (MRI) before surgery. After PM, the specimens were processed by a pathologist. Although a surgicopathological protocol for occult cancer in the PM specimens does not exist, the specimens were divided about 1 cm serially and examined in their entirety.

Results {#Sec3}
=======

Of 1527 registrees who underwent *BRCA* testing, 1125 (73.7%) were negative for *BRCA1*/*2* mutation (*BRCA1*/*2*^*MUT*−^), 297 (19.5%) were positive for *BRCA1*/*2* mutation (*BRCA1*/*2*^*MUT*+^), and 105 (6.9%) had uncertain results. Among the 297 *BRCA1*/*2*^*MUT*+^ subjects (19.5%), 157 (10.3%) carried mutations for *BRCA1*, 139 (9.1%) for *BRCA2*, and 1 (0.1%) was positive for both (Fig. [1](#Fig1){ref-type="fig"}). Among 359 patients with triple-negative breast cancer, 101 (28.3%) had mutations for *BRCA1* and 18 (5.0%) for *BRCA2* (Fig. [2](#Fig2){ref-type="fig"}). Distribution of age at onset of breast cancer with/without *BRCA1*/*2* mutations (Fig. [3](#Fig3){ref-type="fig"}) shows that *BRCA1*/*2*^*MUT*+^ breast cancer occurred at a younger mean age (41.7 years) than did *BRCA1*/*2*^*MUT*−^ breast cancer (45.8 years). In comparison to the 2013 National Registration for Breast Cancer Incidence in Japan (*n* = 76,839) \[[@CR2]\], breast cancer with *BRCA* mutations occurred at a younger age. Among types of *BRCA1*/*2* pathological mutations that were reported more than once, L63X was the most common (Table [1](#Tab1){ref-type="table"}).

Fig. 1Prevalence of *BRCA1*/*2* mutations

Fig. 2Rates of *BRCA1*/*2* mutations in triple-negative breast cancers

Fig. 3Distribution of age at onset of breast cancer with/without *BRCA1*/*2* mutations and national statistics (2013). Mean age at onset of breast cancer. *BRCA1*/*2* mutation positive: 41.7 years; *BRCA1*/*2* mutation negative: 45.8 years

Table 1Types of *BRCA1*/*2* pathological mutations that were reported more than once*BRCA1BRCA2*Base mutationAmino acid mutationReport countBase mutationAmino acid mutationReport countMyriadHGVSMyriadHGVS307T \> Ac.188T \> AL63X405804del4c.5576_5579delTTAASTOP186210Unconfirmed17180C \> Tc.6952C \> TR2318X92919C \> Tc.2800C \> TQ934X138732C \> Ac.8504C \> AS2835X73561delGc.3442delGSTOP11545Unconfirmed1575delCAc.456_457delCASTOP15759345G \> Ac.9117G \> AP3039P62508delGAc.2389_2390delGASTOP79941506delAc.1278delASTOP42963759G \> Tc.3640G \> TE1214X48857G \> Tc.8629G \> TE2877X55083C \> T^b^c.4964C \> TS1655F49304C \> Tc.9076C \> TQ3026X5IVS20-1G \> Ac.5278-1G \> A35873C \> Ac.5645C \> AS1882X5IVS20-1G \> Cc.5278-1G \> C38817insAc.8589dupASTOP286851623del5c.1504_1508delTTAAASTOP50322041delAc.1813dupASTOP6135297C \> Tc.178C \> TQ60X25804del4c.5576_5579delTTAASTOP18614309T \> Cc.190T \> CC64R29610C \> Tc.9382C \> TR3128X35181del3c.5062delGTTV1688del23463delTc.3235delTSTOP108635280C \> Tc.5161C \> TQ1721X2983del4c.755_758delACAGSTOP2753exon1a-2delc.(?\_-1387-1)\_(80 + 1_81 − 1)del24123G \> Tc.3895G \> TE1299X2exon8 delc.(441 + 1_442-1)\_(546 + 1_547-1)del28251A \> G^b^c.8023A \> GI2675V2IVS14-2A \> G^a^c.4485-2A \> G23423del4c.3195_3198delTAATSTOP107522041insAc.1813dupASTOP61523036del4c.2808_2811delACAASTOP9592^a^Suspected deleterious^b^Mixed suspected deleterious and deleterious

To help decide between surgical procedures (total mastectomy vs. breast-conserving surgery \[BCS\]), 370 subjects underwent presurgical genetic testing. Of the 66 *BRCA1*/*2*^*MUT*+^ subjects, 58 (87.9%) chose to undergo total mastectomy, and 8 (12.1%) chose BCS. Of the 304 *BRCA1*/*2*^*MUT*−^ subjects, 141 (46.4%) chose total mastectomy, 158 (52.0%) chose BCS, and 5 had unknown choices (Table [2](#Tab2){ref-type="table"}).

Table 2Genetic testing to select breast cancer surgical procedures (*n* = 418)Testing resultsCases countBreast cancer operation typeBreast-conserving surgeryMastectomyUnknownPositive668\
12.1%58\
87.9%0\
0%Negative304158\
52.0%141\
46.4%5\
1.6%\# of 418 patients, 370 underwent surgery after genetic testing

During the follow-up period, four cases of new-onset breast cancers were observed among the 55 non-affected BRCA carriers (mean observation period: 2.5 years; incidence rate: 2.9%/year; Table [3](#Tab3){ref-type="table"}). Among the 73 *BRCA1*/*2*^*MUT*+^ women who underwent BCS, 3 ipsilateral breast cancer cases were found (mean observation period: 3.5 years; incidence rate: 1.2%/year), compared with only 2 cases among the 477 *BRCA1*/*2*^*MUT*−^ women (mean observation period: 2.2 years; incidence rate: 0.2%/year; Table [4](#Tab4){ref-type="table"}). Of 189 *BRCA1*/*2*^*MUT*+^ women with unilateral breast cancer, 8 contralateral breast cancer cases were found (mean observation period: 3.0 years; incidence rate: 1.4%/year), compared with 4 cases of contralateral breast cancer among 892 *BRCA1*/*2*^*MUT*−^ women (mean observation period: 2.2 years; incidence rate: 0.2%/year; Table [5](#Tab5){ref-type="table"}).

Table 3Breast cancer after genetic testing among non-affected *BRCA* carriersCarriers without a history of breast cancer^a^55 casesObservation period after genetic testing (average)0--13.9 years (2.5)Age at genetic testing (average)Age 20--66 (age 38.6)Breast cancer onset after genetic testing4 casesIncidence rate4/137.5 (persons/person years)\
2.9%/year***BRCA1*** positive 2 cases, ***BRCA2*** positive 2 casesOpportunities for detectionMRI: 2 cases, DCIS\
MMG: 1 case, DCIS\
Self-detection: 1 case, invasive 3.2 cm*DCIS* ductal carcinoma in situ, *MMG* mammography, *MRI* magnetic resonance imaging^a^Including one patient with a history of cervical cancer and another with a history of ureter cancer

Table 4Breast cancers in ipsilateral breasts after breast-conserving surgery*BRCA1*/*2* positive*BRCA1*/*2* negativeWomen with a history of breast-conserving surgery73 cases477 casesIpsilateral breast cancer onset after genetic testing3 cases2 casesObservation period after genetic testing (average)0.01--12.3 years (3.5)0.01--12.5 years (2.2)Incidence rate3/256\
(persons/person years)\
1.2%/year2/1049\
(persons/person years)\
0.2%/yearBackground Age of onset of the first breast cancer (average)Age 19--71 (age 41.7)Age 22--81 (age 46.4) Number of exclusion cases due to PM3 cases0 cases*PM* prophylactic mastectomy

Table 5Contralateral breast cancers among patients treated for unilateral breast cancers*BRCA1*/*2* positive*BRCA1*/*2* negativeWomen with a history of unilateral breast cancer189 cases892 casesContralateral breast cancer onset after genetic testing8 cases4 casesObservation period after genetic testing (average)0.02--16.8 years\
(3.0)0.01--20.2 years\
(2.2)Incidence rate8/567\
(persons/person years)\
1.4%/year4/1962\
(persons/person years)\
0.2%/yearBackground Age of onset of the first breast cancer (average)Age 19--74 (age 41.7)Age 22--85 (age 45.4) Number of exclusion cases due to PM37 cases3 cases*PM* prophylactic mastectomy

Among the 51 patients who underwent PM (Table [6](#Tab6){ref-type="table"}), 6 had specimens in which occult breast cancer was found, including 1 with a *BRCA1* mutation and 5 with *BRCA2* mutations. All six patients had undergone extensive imaging prior to PM, using MMG, US, and breast MRI (Tables [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}). In our study, the rate of occult cancer among total removed breasts by PM was 6/53 = 11.3%.

Table 6Clinicopathological characteristics of patients who underwent prophylactic mastectomies (*n* = 51)Age Mean43.7 Median43 Range30--62*BRCA1* Positive29 cases*BRCA2* Positive18 cases  *BRCA1*/*2* Negative4 casesBreast cancer stage  03 cases  117 cases  214 cases  34 cases  40 case  Non-onset2 cases Uncertain11 casesBreast cancer subtype Hormone positive  HER2 negative11 cases  HER2 positive3 cases  HER2 uncertain8 cases Hormone negative  HER2 positive0 case  HER2 negative23 cases  HER2 uncertain2 cases  Non-onset2 cases  Uncertain2 cases*HER2* human epidermal growth factor receptor 2

Table 7Clinicopathological characteristics of patients in whom occult cancer was found after undergoing prohylactic mastectomiesAge Mean42.2 Median43 Range33--51*BRCA1*1 case*BRCA2*5 casesOccult cancer DCIS5 cases Invasive cancer1 case*DCIS* ductal carcinoma in situ

Table 8Cases of occult cancer in this studyAge*BRCA1* or *2*Size (cm)Type1362NADCIS2472NADCIS3431NADCIS45120.5Invasive5432NADCIS6332NADCIS*DCIS* ductal carcinoma in situ, *NA* not available

Discussions {#Sec4}
===========

We report herein one of the highest incidence rates in the literature: 11.3% of occult cancer in PM specimens, despite thorough presurgical assessment with MRI, US, and MMG, compared with previously reported rates of 0.5--9.9% (Table [9](#Tab9){ref-type="table"}). We reviewed several factors thought to influence occult cancer occurrence, including (a) rates of bilateral prophylactic mastectomy (BPM), (b) pre-PM examination methods, (c) *BRCA1*/*2*^*MUT*+^ rates among subjects, and (d) pathological methods.

Table 9Occult cancers reported in the literatureReferencesSubjects\#% of BRCA\# of BPM\# of Total PMOccult cancer rate by total PM\#Pre-PM examPathological methodHartmann \[[@CR5]\]645NA64512906/1290 (0.5%)NANAMeijers-Heijboer \[[@CR6]\]76100761521/152 (0.7%)\
LCIS:1, No DCIS or IDCPE, MMG, or MRI3 random blocks/quadrantYao \[[@CR7]\]1501001482984/298 (1.3%)\
IDC:1, DCIS:3PE, MMG, or US, All MRINABurger \[[@CR8]\]718.512834/83 (4.8%)\
ILC(3.5 mm):1, LCIS:3NANABoughey \[[@CR9]\]4095.62743622/436 (5.0%)\
IDC:2, ILC:6\
(IDC&ILC:2--9 mm)\
DCIS:14PE, MMG2 section/each quadrant & nipplevan Sprundel \[[@CR10]\]791000794/79 (5.1%)\
IDC(32 mm):1, DCIS:3PE, radiologicalNAMcLaughlin \[[@CR11]\]5299.38461333/613 (5.4%)\
IDC:10, DCIS:23PE, MMG, (US and/or MRI), (235/529pts: MRI)2 section/each quadrant & nippleEvans \[[@CR12]\]10510001056/105 (5.7%)\
IDC:4, DCIS:2NANAHoogerbrugge \[[@CR13]\]67664110810/108 (9.3%)\
IDC(4 mm):1\
DCIS(2--40 mm):9\
(17/67pts: LCIS)^a^PE, MMG, 4/10pts MRI, (27/67pts: MRI)5 mm slices and radiological exam, then suspicious lesions and randomly selected each quadrant and nipple (Ave. 19 slides)Kauff \[[@CR14]\]241007313/31 (9.7%)\
DCIS(7--20 mm):3\
(LCIS: 1)^a^MMG2--4 section/each quadrant& nippleBlack \[[@CR15]\]173171919219/192 (9.9%)\
IDC(1.5--10 mm):5, DCIS:1459/173pts MRINAOur study51922536/53 (11.3%)\
IDC(5 mm):1, DCIS:5PE, MMG, US & MRIAbout 1 cm slices*BPM* bilateral prophylactic mastectomy, *DCIS* ductal carcinoma in situ, *IDC* invasive ductal carcinoma, *ILC* invasive lobular carcinoma, *LCIS* lobular carcinoma in situ, *MMG* mammography, *MRI* magnetic resonance imaging, *NA* not available, *PE* physical examination, *PM* prophylactic mastectomy, *US* ultrasound^a^LCIS were detected, but not included, as occult cancer cases, as they may co-exist with DCIS

Rates of BPM {#Sec5}
------------

Rates of BPM among subjects in the first three studies of Table [9](#Tab9){ref-type="table"} are higher (at or near 100%) than in the other studies. The retrospective study of Hartmann et al. \[[@CR5]\] included all women with family histories of breast cancer who underwent BPM in USA between 1960 and 1993. They found only 0.5% of occult cancer after BPM, though the rate of *BRCA* mutations among their subjects was not available. Meijers-Heijboer et al. \[[@CR6]\] conducted a prospective study of 139 women with pathogenic *BRCA1* or *BRCA2* mutations who were enrolled in a breast-cancer surveillance program, Netherlands. Of the 139, 76 underwent PM from 1992 to 2001. They found only 1 case of lobular carcinoma in situ \[LCIS (0.7%)\] and no cases of ductal carcinoma in situ (DCIS) or invasive ductal carcinoma (IDC), even among *BRCA1*/*2*^*MUT*^ carriers. The study of Yao et al. \[[@CR7]\] was a retrospective review of pathology results and outcomes of 201 *BRCA1*/*2*^*MUT*^ carriers, in USA, treated between 2007 and 2014 (1.3% occult cancer among 150 *BRCA1*/*2*^*MUT*^ carriers \[298 breasts\] undergoing nipple-sparing PMs). The much higher rates of BPM in these three studies seem to have resulted in much lower occult cancer rates (0.5--1.3%) than in the other studies. BPM patients are considered to have no history of breast cancer.

In contrast, van Sprundel et al. \[[@CR10]\] in the Netherlands found 5% occult cancer among 79 of 148 patients who underwent contralateral prophylactic mastectomy (CPM). The 148 patients were identified until June 2003 as carrying *BRCA1* or *BRCA2* mutations with previous histories of unilateral, stage I--IIIa invasive breast cancer. Evans et al. \[[@CR12]\] in UK between 1985 and 2010, considered whether CPM improves overall survival, and found 5.7% occult cancer in 105 women with *BRCA1*/*2* mutations and unilateral breast cancer who underwent CPM. By comparing the 100% (or near-100%) BPM cohorts with 100% CPM cohorts, we see that high rates of BPM might be associated with lower rates of occult cancer. Therefore, even among *BRCA* carriers, detection rate of occult cancer may have been influenced by the status whether affected or non-affected.

Pre-PM examination methods {#Sec6}
--------------------------

Black et al. \[[@CR15]\] of USA reviewed occult malignancy in 192 PMs in 173 patients treated from 1999 to 2005, to compare pre-operative MRI with sentinel lymph node biopsy (SLNB), and found that MRI (performed in 59 patients) missed three of four total occult cancers. In the study of McLaughlin et al. \[[@CR11]\] (USA) of 529 patients who underwent 613 PMs between 1999 and 2006, both pre-operative MRI and SLNB were performed selectively at the discretion of the surgeon; they reported the sensitivity of MRI for detecting occult cancers to be 78%. In a 2015 study, Riedl et al. \[[@CR17]\] insisted that the use of MRI to screen women at increased risk for breast cancer improved detection of invasive cancers and DCIS, regardless of mutation status, age, or breast density; their improved results for MRI sensitivity might be explained by technical advances, improved diagnostic criteria, and greater familiarity of radiologists in reading breast MRIs, including the ability to diagnose DCIS with MRI \[[@CR17], [@CR18]\].

Regarding US, Bosse et al. \[[@CR19]\] reported with respect to *BRCA1*/*2*^*MUT*^ carriers, that the sensitivity of US was 77%, and that of MRI was 100%. Ohuchi et al. \[[@CR20]\] from Japan reported that the sensitivity of MMG + US for asymptomatic women aged 40--49 years with no history of any cancer in the previous 5 years was 91.1%.

With regard to MRI + MMG + US (yearly MRI, MMG, and biannual US), van Zelst et al. \[[@CR21]\] reported the sensitivity to be 76.3% for surveillance of *BRCA1*/*2*^*Mut*+^ women and their first-degree untested relatives. Riedl et al. \[[@CR17]\] reported the sensitivity to be 95.0%, among *BRCA1*/*2*^*Mut*+^ carriers and women with a familial risk \> 20% (US was offered to *BRCA* mutation carriers). Kuhl et al. \[[@CR22]\] reported the sensitivity to be 100%, in a high-risk population (370 of 687 patients underwent US). Our study is the only report to unitize MRI, US, and MMG before PM. However, occult cancers were found in 11.3% of all removed breasts at the time of PM, which indicates that the sensitivity of MRI + MMG + US is not 100% as reported by Kuhl et al. There seem to be limitations of combination surveillance modalities including MRI for patients with *BRCA* mutations.

BRCA1/2^MUT+^ rates {#Sec7}
-------------------

*BRCA* mutation rates and occult cancer rates do not seem to be related in the studies cited in Table [9](#Tab9){ref-type="table"}. For example, in the study of Burger et al. \[[@CR8]\] on women who underwent PM (*n* = 83 in 71 patients) and SLNB (*n* = 1522 in 1498 patients) between 2005 and 2010 in UK, the rate of *BRCA* mutation in the 71 patients was 8.5% and the occult cancer rate was 4.8%, which is similar to 5% reported by van Sprundel et al. \[[@CR10]\] among a 100% *BRCA1*/*2*^*MUT*+^ population. Kauff et al. \[[@CR14]\] compared prevalence of histopathologic lesions in PM (performed between 1987 and 2001 in USA) specimens from women with *BRCA* mutations and in age and race-matched cadaver mastectomy specimens and found that high-risk epithelial proliferative lesions (including DCIS) are more common in the unaffected breasts of women with known *BRCA* mutations than in women of the comparison group. However, they said that determining whether these lesions are more common in women with *BRCA* mutations than in those without will require direct comparison to women without mutations or with low risk for carrying mutations.

Pathological methods {#Sec8}
--------------------

Pathological examination methods vary among the papers cited in Table [9](#Tab9){ref-type="table"}. Some studies evaluated 2--4 sections per quadrant of the breast and a section of the nipple, and another evaluated them by 5 mm slices and radiological examination; the methods of the others are not known. Boughey et al. \[[@CR9]\] examined specimens (from PMs, between 2000 and 2005, USA) of at least 2 sections per each quadrant and nipple; the specimens were also macroscopically sliced and any areas found abnormal by palpation were evaluated further at the pathologists' discretion. They noted a 5% occult cancer rate, including 2 IDCs. In the study of Hoogerbrugge et al. \[[@CR13]\], the specimens (from PM between 1989 and 2001, Netherlands) were cooled and sliced in serial sections with approximately 5 mm intervals. Radiographs were made from the tissue slices. Suspicious lesions and randomly selected areas from each quadrant and the nipple were sampled, with a mean number of 19 samples per specimen. With this method, they detected 9.3% occult cancer including one 4 mm IDC, and the occult cancer rate would have been higher than 9.3% if LCIS were counted. In the other studies, more detailed pathological examinations might have detected higher occult cancer rates. In the current study, we divided PM specimens about 1 cm serially and then, examined their entirety, and noted 11.3% occult cancer, including a 5 mm IDC. At present, there is not a strict histopathological protocol for PM specimens. However, there exist pathological guidelines for ovarian cancer \[[@CR23]\]. Similarly, standardized guidelines for examining PM specimens may be required, as we might easily have missed the aforementioned-5-mm occult cancer. In addition to this, occult cancer should be defined in the protocol, for example, as to whether LCIS can be included in the occult cancer.

This investigation is limited by the fact that it is a registration study from seven institutions and may not fairly reflect the entire population of Japanese *BRCA* mutation carriers.

Conclusions {#Sec9}
===========

Our report showed a relatively higher incidence rate of occult cancer at 11.3% in PM specimens despite thorough pre-operative radiological evaluations, which included a breast MRI. Considering the occult cancer rates and the various pathological methods of our study and published studies, we propose the necessity of a histopathological protocol.

We are grateful to Dr. Akihiro Sakurai (Sapporo Medical University), Drs. Takayuki Enomoto and Masayuki Sekine (Niigata University Graduate School of Medical and Dental Sciences), Dr. Tadashi Nomizu (Hoshi General Hospital), and Dr. Junko Yotsumoto (Ochanomizu University) for supporting us as members of the registration committee of the Japanese HBOC Consortium.

This work was supported by Health, Labour and Welfare Sciences Research Grants (H29-policy for cancer-general-003) and AMED (18 cm0106503h0003).

Conflict of interest {#FPar1}
====================

The authors claim no conflicts of interest.

Ethical approval {#FPar2}
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Japanese HBOC Consortium Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent {#FPar3}
================

Informed consent was obtained from all individual participants included in the study.
